Long-Term Outcome of Initially Unresectable Metastatic Colorectal Cancer Patients Treated with 5-Fluorouracil/Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Followed by Radical Surgery of Metastases

Masi, Gianluca; Loupakis, Fotios; Pollina, Luca Emanuele; Vasile, Enrico; Cupini, Samanta; Ricci, Sergio; Brunetti, I.; Ferraldeschi, Roberta; Naso, Giuseppe; Filipponi, Franco; Pietrabissa, Andrea; Goletti, Orlando; Baldi, Giacomo Giulio; Fornaro, Lorenzo; Andreuccetti, M.; Falcone, Alfredo

doi:10.1097/sla.0b013e31819a0486

Cited by 217 publications

(137 citation statements)

References 27 publications

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…In the case of FOLFOXIRI, the great majority of patients had been given a second chemotherapy regimen after progression, and it was shown in a recent study that the use of FOLFOXIRI as first-line treatment does not compromise the administration and the efficacy of second-line treatment [25,26]. In our study as well, most patients (n ϭ 28, 67%) had second-line therapy, whereas 13 patients (31%) had received third-line treatment at the time of analysis.…”

Section: Discussionmentioning

confidence: 99%

Cetuximab Plus FOLFIRINOX (ERBIRINOX) as First-Line Treatment for Unresectable Metastatic Colorectal Cancer: A Phase II Trial

et al. 2011

View full text Add to dashboard Cite

Background. Triplet chemotherapy has demonstrated manageable toxicities and a favorable response rate. The addition of cetuximab to chemotherapy can increase treatment efficacy. We evaluated the efficacy and safety of cetuximab plus 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOL-FIRINOX), the ERBIRINOX regimen, as first-line treatment in patients with unresectable metastatic colorectal cancer (mCRC).Patients and Methods. In a phase II study, treatment consisted of weekly cetuximab plus biweekly. Treatment was continued for a maximum of 12 cycles and tumor response was evaluated every four cycles. The primary efficacy criterion was the complete response (CR) rate.

show abstract

Section: Discussionmentioning

confidence: 99%

Cetuximab Plus FOLFIRINOX (ERBIRINOX) as First-Line Treatment for Unresectable Metastatic Colorectal Cancer: A Phase II Trial

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Standard combination chemotherapy regimens comprising 5-fluorouracil (5-FU) plus leucovorin [LV] in combination with irinotecan, typically FOLFIRI or oxaliplatin (FOLFOX) have been reported to facilitate the resection of 9-40 % of initially unresectable metastases, and a median survival of 15 to 20 months [7][8][9]. Although, intensified chemotherapy such as FOLFOXIRI (i.e., oxaliplatin, 5-FU/LV and irinotecan) has been shown to have high response and conversion rates (19 %); however, it has not been generally recommended thus far due to its considerable toxicity [10]. For patients with disease progression during preoperative chemotherapy predicts poor prognosis, for which a change to other alternative chemotherapy regimens is recommended [11].…”

Section: Introductionmentioning

confidence: 99%

Assessment of Tumor Response and Resection Rates in Unresectable Colorectal Liver Metastases Following Neoadjuvant Chemotherapy with Cetuximab

Somashekhar

Ashwin

Zaveri

et al. 2015

Indian J Surg Oncol

View full text Add to dashboard Cite

To investigate efficacy and safety of cetuximab combined with neo adjuvant chemotherapy regimen in patients with unresectable colorectal liver. This was a prospective trial with rate of Ro liver metastases resection as primary end point. Between January 2010 and December 2014, 46 patients with unresectable liver metastases from colon or rectum were enrolled. Patients received Cetuximab along with neoadjuvant chemotherapy where 34 (74 %) and 12 (26 %) patients received FOLFOX and FOLFIRI, respectively. They were assessed for response after 2-3 cycles by CT scan. Patients with resectable disease were offered liver surgery within 3-6 weeks of the last treatment cycle. The primary end point was resection rate of liver metastases, which was evaluated in all patients. Secondary end points were response rate according to Response evaluation criteria in solid tumors (RECIST) criteria, perioperative morbidity and mortality. An objective response was observed in 28 (60.9 %) patients. Seven (15.2 %) patients were reported radiologically to have a complete response (CR); 21 (45.7 %) patients had radiological partial response (PR). An additional 12 patients (26.1 %) demonstrated stable disease (SD) and only six patients (13.0 %) had disease progression (PD). Microscopically complete resections (R0 resection) was performed in all 28 patients (60.9 %). The most frequent toxicities were skin rash and diarrhoea. There was no operative mortality. Chemotherapy with cetuximab yields high response rates compared with historical controls, and leads to significantly increased resectability. Complete resection of previously unresectable colorectal liver metastases can be performed with minimal morbidity and mortality. This therapeutic strategy involves a multimodal approach.

show abstract

“…Ряд работ посвящен изучению трехкомпонентных режимов химиотерапии при метастатическом колорек-тальном раке [25][26][27][28]. В упоминавшемся ранее исследо-вании GONO применение режима FOLFOXIRI приводило не только к большей частоте объективных эффектов по сравнению с FOLFIRI (60% против 34% соответственно), но и позволило достоверно увеличить число радикаль-ных резекций печени с 12% при лечении FOLFIRI до 36% при FOLFOXIRI (р = 0,017).…”

Section: пациенты с потенциально резектабельными метастазами в печениunclassified

“…Серьезных послеоперационных осложнений не было. Стеатогепатит отмечен только у 5% больных [26]. Интенсивный режим влиял на выживаемость больных: медиана продолжи-тельности жизни составила 22,6 мес.…”

Section: пациенты с потенциально резектабельными метастазами в печениunclassified

Chemotherapy in the Management of Localized and Metastatic Colon Cancer: New and Yet Unforgotten Approaches

Доброва¹,

Гордеева²,

Черноглазова³

et al. 2017

Medicinskij sovet

View full text Add to dashboard Cite

За последние пару десятков лет мы стали свидетелями существенного прогресса в лечении метастатического колоректального рака: появление новых таргетных препаратов и дифференцированного подхода к их назначению, расширение показаний к резекции метастазов в печени и легких привели к увеличению продолжительности жизни пациентов этой группы. Тем не менее химиотерапия остается основой лекарственного лечения рака толстой кишки. В данной работе мы рассматриваем ряд новых подходов, касающихся применения химиотерапии при III и IV стадиях заболевания.Ключевые слова: метастатический колоректальный рак, рак толстой кишки, химиотерапия, оксалиплатин, 5-фторурацил, иринотекан. CHEMOTHERAPY IN THE MANAGEMENT OF LOCALIZED AND METASTATIC COLON CANCER: NEW AND YET UNFORGOTTEN APPROACHESOver the course of the past couple of decades, we have witnessed some significant improvements in the treatment of metastatic colorectal cancer: the emergence of novel targeted drugs and a differentiated approach to their administration, the extension of indications for surgical resection for liver and lungs metastases has resulted in the increased life expectancy among patients in this group. Nevertheless, chemotherapy remains the treatment of choice for colon cancer. In this paper, we discuss new approaches to the use of chemotherapy on stages III and IV of colorectal cancer.

show abstract

Long-Term Outcome of Initially Unresectable Metastatic Colorectal Cancer Patients Treated with 5-Fluorouracil/Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Followed by Radical Surgery of Metastases

Cited by 217 publications

References 27 publications

Cetuximab Plus FOLFIRINOX (ERBIRINOX) as First-Line Treatment for Unresectable Metastatic Colorectal Cancer: A Phase II Trial

Cetuximab Plus FOLFIRINOX (ERBIRINOX) as First-Line Treatment for Unresectable Metastatic Colorectal Cancer: A Phase II Trial

Assessment of Tumor Response and Resection Rates in Unresectable Colorectal Liver Metastases Following Neoadjuvant Chemotherapy with Cetuximab

Chemotherapy in the Management of Localized and Metastatic Colon Cancer: New and Yet Unforgotten Approaches

Contact Info

Product

Resources

About